| Literature DB >> 33295106 |
Caterina Maffeis1,2, Daniel Armando Morris2, Evgeny Belyavskiy2, Martin Kropf2, Aravind Kumar Radhakrishnan2, Veronika Zach2,3, Cristina Rozados da Conceicao2,3, Tobias Daniel Trippel2,3, Elisabeth Pieske-Kraigher2, Andrea Rossi1, Burkert Pieske2,3,4,5, Frank Edelmann2,3,5.
Abstract
AIMS: Exercise intolerance is the leading manifestation of heart failure with preserved or mid-range ejection fraction (HFpEF or HFmrEF), and left atrial (LA) function might contribute to modulating left ventricular filling and pulmonary venous pressures. We aim to assess the association between LA function and maximal exercise capacity in patients with HFpEF or HFmrEF. METHODS ANDEntities:
Keywords: Cardiopulmonary exercise test; Heart failure; Left atrial strain; Mid-range ejection fraction; Preserved ejection fraction
Mesh:
Year: 2020 PMID: 33295106 PMCID: PMC7835603 DOI: 10.1002/ehf2.13143
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Figure 1Left atrial function assessed by the speckle tracking echocardiography. Example of three‐beat strain curves in the three atrial segments in apical four‐chamber view. The mean value of the first positive peak of the three curves represent the reservoir strain, and that of the second lower positive peak represents the contractile strain.
Demographic and clinical characteristics and cardiopulmonary exercise test variables
| Peak VO2 < 14 mL/kg/min ( | Peak VO2 ≥ 14 mL/kg/min ( |
| |
|---|---|---|---|
| Age, years | 75 ± 6 | 70 ± 9 | 0.03 |
| Male sex, | 14 (48) | 23 (64) | 0.2 |
| Body mass index, kg/m2 | 30 ± 5 | 26 ± 4 | 0.002 |
| Systolic blood pressure, mmHg | 132 ± 18 | 141 ± 22 | 0.09 |
| Heart rate, bpm | 68 ± 9 | 65 ± 10 | 0.3 |
| Atrial fibrillation, | 8 (28) | 7 (19) | 0.4 |
| NYHA class III, | 10 (34) | 2 (5) | 0.003 |
| Medical history | |||
| Hypertension, | 27 (93) | 31 (86) | 0.3 |
| Dyslipidaemia, | 22 (76) | 18 (50) | 0.04 |
| Diabetes mellitus, | 10 (34) | 12 (33) | 0.9 |
| Sleep apnoea syndrome, | 1 (3) | 9 (25) | 0.02 |
| Smoke, | 13 (45) | 20 (56) | 0.5 |
| Ischaemic heart disease, | 15 (52) | 18 (50) | 0.9 |
| Valve percutaneous intervention, | 7 (24) | 4 (11) | 0.1 |
| Peripheral artery disease, | 3 (10) | 3 (8) | 0.8 |
| Stroke/TIA, | 4 (14) | 6 (16) | 0.7 |
| Chronic obstructive pulmonary disease, | 4 (14) | 2 (5) | 0.3 |
| Chronic liver disease, | 1 (3) | 0 (0) | 0.3 |
| Chronic kidney injury, | 9 (31) | 7 (19) | 0.3 |
| Medications | |||
| ACE inhibitors or ARBs, | 22 (76) | 31 (86) | 0.3 |
| Beta‐blockers, | 25 (86) | 27 (75) | 0.3 |
| Anti‐aldosterone, | 5 (17) | 9 (25) | 0.4 |
| Diuretics, | 22 (76) | 19 (52) | 0.06 |
| Laboratory | |||
| Haemoglobin, g/dL | 13.4 ± 1.2 | 13.5 ± 1.4 | 0.7 |
| Total cholesterol, mg/dL | 159 ± 41 | 180 ± 51 | 0.08 |
| LDL cholesterol, mg/dL | 95 ± 32 | 114 ± 49 | 0.08 |
| HbA1c, % | 5.5 ± 0.9 | 5.5 ± 0.9 | 0.9 |
| Creatinine, mg/dL | 1.1 ± 0.4 | 1.0 ± 0.4 | 0.4 |
| Hs‐C‐reactive protein, mg/L | 2.6 ± 3.0 | 4.2 ± 6.8 | 0.3 |
| Ferritin, μg/L | 113 ± 82 | 115 ± 100 | 0.9 |
| NT‐proBNP, pg/mL | 640 (436–1022) | 413 (249–786) | 0.01 |
| Cardiopulmonary exercise test | |||
| Maximal work, Watt | 75 ± 16 | 111 ± 27 | <0.0001 |
| Time of exercise, min | 7 ± 1 | 11 ± 3 | <0.0001 |
| Peak VO2, mL/kg/min | 12.4 ± 1.5 | 19.4 ± 4.0 | <0.0001 |
| Percent predicted peak VO2, % | 74 ± 16 | 94 ± 18 | <0.0001 |
| Peak RER | 1.05 ± 0.03 | 1.05 ± 0.05 | 0.5 |
| VE/VCO2 slope | 39 ± 7 | 34 ± 6 | 0.001 |
| Rest heart rate, bpm | 73 ± 13 | 69 ± 10 | 0.1 |
| Exercise maximal heart rate, bpm | 102 ± 21 | 121 ± 25 | 0.002 |
| Δheart rate, bpm | 30 ± 18 | 52 ± 21 | <0.0001 |
| Borge score (6–20) | 15.6 ± 2.2 | 15.9 ± 1.7 | 0.6 |
ACE, angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers; NT‐proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association; RER, respiratory exchange ratio; TIA, transient ischaemic attack.
Echocardiographic parameters
| Peak VO2 < 14 mL/kg/min ( | Peak VO2 ≥ 14 mL/kg/min ( |
| Coefficient for correlation with peak VO2, mL/kg/min |
| |
|---|---|---|---|---|---|
| LV structure and function | |||||
| LV EDV‐i, mL/m2 | 51 ± 16 | 57 ± 14 | 0.2 | 0.10 | 0.5 |
| LV‐mass‐i, g/m2 | 109 ± 23 | 112 ± 32 | 0.7 | −0.07 | 0.6 |
| RWT | 0.45 ± 0.07 | 0.45 ± 0.09 | 0.8 | −0.05 | 0.7 |
| LVEF, % | 60 ± 9 | 59 ± 8 | 0.9 | 0.13 | 0.3 |
| LV GLS, % | −17.9 ± 3.6 | −18.3 ± 2.9 | 0.7 | −0.12 | 0.4 |
| S′, cm/s | 6.1 ± 1.3 | 6.8 ± 1.6 | 0.09 | 0.27 | 0.03 |
| SV‐LVOT‐i, mL/m2 | 27 ± 5 | 32 ± 7 | 0.008 | 0.21 | 0.1 |
| LA structure and function | |||||
| LAV‐max‐i, mL/m2 | 45 ± 17 | 47 ± 22 | 0.6 | −0.07 | 0.6 |
| LAV‐min‐i, mL/m2 | 29 ± 14 | 30 ± 19 | 0.8 | −0.08 | 0.5 |
| LA EF, % | 35 ± 10 | 39 ± 13 | 0.1 | 0.19 | 0.1 |
| LA reservoir strain, % | 14 ± 5 | 21 ± 9 | 0.002 | 0.36 | 0.003 |
| LA conduit strain, % | 9 ± 2 | 13 ± 4 | 0.001 | 0.29 | 0.04 |
| LA contractile strain, % | 7 ± 4 | 11 ± 6 | 0.02 | 0.33 | 0.02 |
| LA systolic SR, %/s | 0.6 ± 0.2 | 0.7 ± 0.3 | 0.01 | 0.32 | 0.01 |
| LA early diastolic SR, %/s | −0.4 ± 0.1 | −0.5 ± 0.2 | 0.03 | −0.16 | 0.2 |
| LA late diastolic SR, %/S | −0.5 ± 0.2 | −0.6 ± 0.3 | 0.1 | −0.29 | 0.04 |
| Doppler | |||||
| E, cm/s | 83 ± 32 | 76 ± 23 | 0.3 | −0.21 | 0.1 |
| A, cm/s | 76 ± 26 | 70 ± 24 | 0.4 | −0.09 | 0.5 |
| DTE, ms | 213 ± 73 | 213 ± 51 | 0.9 | 0.08 | 0.5 |
| E/A | 1.1 ± 0.6 | 1.1 ± 0.7 | 0.9 | −0.13 | 0.4 |
| E´, cm/s | 6.5 ± 1.8 | 6.3 ± 1.8 | 0.7 | 0.01 | 0.9 |
| E/e´ | 13.1 ± 4.7 | 13.0 ± 6.0 | 0.9 | −0.16 | 0.2 |
| MR, | 25 (86) | 23 (64) | 0.05 | −0.21 | 0.04 |
| TR, | 23 (79) | 23 (64) | 0.1 | −0.09 | 0.1 |
| Peak TR velocity, m/s | 2.7 ± 0.6 | 2.4 ± 0.4 | 0.08 | −0.31 | 0.03 |
| SPAP, mmHg | 37 ± 19 | 29 ± 10 | 0.1 | −0.30 | 0.06 |
DTE, E wave deceleration time; EDV‐i, Simpson‐biplane end‐diastolic volume index; EF, Simpson‐biplane ejection fraction; GLS, global endocardial longitudinal strain [GLS was measured in apical four‐chamber and two‐chamber view and averaged; biplane GLS was available in 54 (79%) patients]; LAV, left atrial volume; LV, left ventricular; RWT, relative wall thickness; SPAP, systolic pulmonary artery pressure [TR velocity and SPAP were measurable in 46 (68%) of total patients, 92% of patients with TR]; SR, strain rate; SV‐LVOT, left ventricular outflow tract stroke volume; TR, tricuspid regurgitation [it was present in 50 (77%) patients].
Figure 2Association of left atrial reservoir strain and contractile strain (A), left ventricular ejection fraction and left ventricular global longitudinal strain (B), and E/e´ and left atrial volume index (C) with peak VO2 (mL/kg/min).
Pearson correlation of left atrial reservoir strain with echocardiographic variables
| Correlation coefficient |
| |
|---|---|---|
| LA structure and function | ||
| LAV‐max‐i, mL/m2 | −0.49 | <0.0001 |
| LAV‐min‐i, mL/m2 | −0.59 | <0.0001 |
| LA EF, % | 0.77 | <0.0001 |
| LA conduit strain, % | 0.78 | <0.0001 |
| LA contractile strain, % | 0.88 | <0.0001 |
| LA systolic SR, %/s | 0.89 | <0.0001 |
| LA early diastolic SR, %/s | −0.46 | <0.0001 |
| LA late diastolic SR, %/s | −0.75 | <0.0001 |
| LV structure and function | ||
| LV EDV‐i, mL/m2 | 0.21 | 0.08 |
| LV‐mass‐i, g/m2 | −0.15 | 0.2 |
| LVEF, % | −0.01 | 0.9 |
| LV GLS, % | −0.13 | 0.3 |
| LV S′, cm/s | 0.39 | 0.001 |
| SV‐LVOT‐i, mL/m2 | 0.30 | 0.03 |
| E, cm/s | −0.30 | 0.02 |
| A, cm/s | 0.32 | 0.02 |
| DTE, ms | 0.09 | 0.5 |
| E/A | −0.39 | 0.005 |
| E´, cm/s | −0.25 | 0.05 |
| E/e´ | −0.03 | 0.8 |
DTE, E wave deceleration time; EDV‐i, Simpson‐biplane end‐diastolic volume index; EF, ejection fraction; GLS, global endocardial longitudinal strain; LAV, left atrial volume; LV, left ventricular; SR, strain rate; SV‐LVOT, left ventricular outflow tract stroke volume; TR, tricuspid regurgitation.
Figure 3Association of LV and LA parameters with severely reduced exercise capacity (peak VO2 < 14 mL/kg/min). Logistic regression analysis for predictability of peak VO2 < 14 mL/kg/min: LVEF 1 unit (%) decrease odds ratio (OR) 95% confidence interval (CI) 0.99 (0.93–1.05), LV mass index 1 unit (g/m2) increase OR 95% CI 0.99 (0.98–1.01), LA volume index 1 unit (mL/m2) increase OR 95% CI 0.99 (0.97–1.02), LA reservoir strain 1 unit (%) decrease OR 95% CI 1.12 (1.03–1.20), E/e´ 1 unit increase OR 95% CI 1.01 (0.91–1.10). LA, left atrium; LVEF, left ventricular ejection fraction.
Linear regression analysis for association between left atrial reservoir strain and peak VO2 according to different patient selection criteria
| LA reservoir strain, % | 2016 ESC HF guideline ( | 2020 HFA of the ESC consensus recommendation ( | LVEF ≥ 50%, sinus rhythm, without valve procedure ( |
|---|---|---|---|
| Unadjusted |
|
|
|
| Adjusted for age, sex, BMI |
|
|
|
BMI, body mass index; CI, confidence interval; ESC, European Society of Cardiology; HFA, Heart Failure Association; LA, left atrium; LVEF, left ventricular ejection fraction.